Enoxaparin Versus Unfractionated Heparin in PCI

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00439855

Enrollment

2100

Registered

2007-02-26

Start date

2003-09-30

Completion date

2006-02-28

Last updated

2007-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Keywords

Enoxaparin, heparin, hemorrhages

Brief summary

Enoxaparin 0.75mg/kg BW is not inferior to weight adjusted unfractionated heparin as anticoagulation for PCI

Interventions

DRUGEnoxaparin i.v.

DRUGunfractionated heparin

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* PCI for stable ischemia or ACS

Exclusion criteria

* Cardiogenic shock, * Pretreatment with study drugs, * Lack of informed consent

Design outcomes

Primary

Measure	Time frame
Quadruple endpoint: death, MI, urgent TVR, major bleeding	—

Secondary

Measure	Time frame
major bleeding, minor bleeding, thrombocytopenia	—

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026